Less Radical podcast: The origins of modern surgery, radical mastectomy, and the first randomized trials in breast cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Less Radical tells the story of surgeon-scientist Bernie Fisher, who revolutionized breast cancer treatment and transformed the way we understand cancer. 

He was a scrappy young  surgeon—a Jewish kid from Pittsburgh who had to make it past antisemitic quotas to get into med school. 

And the thanks he received for his discoveries? 

A performative, misguided Congressional investigation that destroyed his reputation and haunted him until his death.

Stacy Wentworth

In the first episode, Less Radical host and producer Stacy Wentworth introduces Fisher and his unlikely run-in with the outspoken First Lady Betty Ford in the midst of her breast cancer treatment. 

But that fall weekend in Sept. 1974 helped to alter America’s attitude toward breast cancer, which had previously only been spoken about in hushed tones.  

Episodes two and three cover the origins of modern surgery, the man who developed the Halsted radical mastectomy, and Fisher’s takeaways from the wreckage of the first randomized clinical trial in patients with breast cancer.

At the end of the 19th century, a New York surgeon determined that the only way to cure breast cancer was with radical surgery. For the next hundred years, millions of breast cancer survivors bore the mark of his disfiguring approach.

Episode 2: The Knife is the Cure
Less Radical, Oct. 2, 2024

In 1958, Bernie Fisher participated in the first randomized clinical trial in patients with breast cancer. The trial was a disaster, leading most surgeons to abandon chemotherapy. Bernie, however, noticed something different in the data, which leads him on a path that will change the course of cancer treatment forever.

Episode 3: Microbe Hunters and Magic Bullets
Less Radical, Oct. 11, 2024 

All three published episodes—plus a bonus episode—are now available on the Cancer History Project

Over a total of six episodes, Wentworth takes listeners into operating rooms, through the halls of Congress, and into the labs where breakthrough cancer treatments were not only developed, but discovered.

Wentworth is a clinical associate in the Department of Radiation Oncology at Duke University School of Medicine, author, and founder of the substack Cancer Culture.


This column features the latest posts to the Cancer History Project by our growing list of contributors

The Cancer History Project is a free, web-based, collaborative resource intended to mark the 50th anniversary of the National Cancer Act and designed to continue in perpetuity. The objective is to assemble a robust collection of historical documents and make them freely available.  

Access to the Cancer History Project is open to the public at CancerHistoryProject.com. You can also follow us on Twitter at @CancerHistProj, or follow our podcast.

Is your institution a contributor to the Cancer History Project? Eligible institutions include cancer centers, advocacy groups, professional societies, pharmaceutical companies, and key organizations in oncology. 

To apply to become a contributor, please contact admin@cancerhistoryproject.com.

Table of Contents

YOU MAY BE INTERESTED IN

Over the past five years, Cedars-Sinai Cancer has built an integrated, regional system designed to provide cancer care close to where patients live and work. This model of care, directed by an academic medical center to patients at the community level, proved to be the best possible approach to supporting patients in our 11-million-person catchment area during the worst fire disaster in California history. 
In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine, also referred to as T-DM1) reduced the long-term risk of death or invasive disease by 46% and improved survival compared to trastuzumab alone, according to the final results of the phase III KATHERINE clinical trial led by researchers from the University of Pittsburgh and UPMC Hillman Cancer Center. 
The Groupe d’Oncologie Radiothérapie Tête Et Cou, also known as the Head and Neck Oncology and Radiotherapy Group or GORTEC, announced that the randomized phase III CheckMate -9KW/NIVOPOSTOP GORTEC 2018-01 trial evaluating nivolumab (Opdivo) as a post-operative treatment component for resected patients with locally advanced squamous cell carcinoma of head and neck with high risk of relapse met its primary endpoint of disease-free survival across all comers.  
Artificial Intelligence can improve breast cancer detection and reduce workload on physicians, according to a new study featuring over 461,000 women. The research published in the journal Nature Medicine looked at integrating an AI tool as part of a national screening program for women without symptoms of breast cancer in Germany.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login